Antiprotozoal compounds: state of the art and new developments

被引:34
作者
Astelbauer, F. [1 ]
Walochnik, J. [1 ]
机构
[1] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria
关键词
Amoebiasis; Chagas disease; Chemotherapy; Leishmaniasis; Malaria; Sleeping sickness; ARTEMISININ-RESISTANT MALARIA; LIPOSOMAL AMPHOTERICIN-B; CHRONIC CHAGAS-DISEASE; LEISHMANIA-DONOVANI; PLASMODIUM-FALCIPARUM; ANTIMALARIAL-DRUGS; TRYPANOSOMA-CRUZI; VISCERAL LEISHMANIASIS; CHLOROQUINE; EFFICACY;
D O I
10.1016/j.ijantimicag.2011.03.004
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Protozoa can cause severe diseases, including malaria, leishmaniasis, Chagas disease, sleeping sickness and amoebiasis, all being responsible for morbidity and mortality particularly in tropical countries. To date there are no protective vaccines against any of these diseases, and many of the available drugs are old or elicit serious adverse reactions. Moreover, parasite resistance to existing drugs has become a serious problem. Owing to lack of financial returns, research in this field is of limited interest to pharmaceutical companies and largely depends on funding by public authorities. This article aims to provide a concise overview of the state-of-the-art treatment for the most important tropical protozoal infections as well as new approaches. (c) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 82 条
[1]
Breaking down the blood-brain barrier: signaling a path to cerebral malaria? [J].
Adams, S ;
Brown, H ;
Turner, G .
TRENDS IN PARASITOLOGY, 2002, 18 (08) :360-366
[2]
Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases [J].
Al-Abdely, HM ;
Graybill, JR ;
Loebenberg, D ;
Melby, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) :2910-2914
[3]
ALSAFFER R, OVERVIEW EVIDENCE SA
[4]
[Anonymous], 2009, WORLD MAL REP 2009
[5]
[Anonymous], 2010, Guidelines for the treatment of Malaria, DOI DOI 10.1080/03630269.2023.2168201
[6]
*AST PHARM US, 2010, AMBISOME
[7]
BALMER JA, 2009, INT J GYNECOL OBSTET, P11
[8]
Bansal D, 2006, INDIAN J MED RES, V123, P115
[9]
Liposomal amphotericin B for the treatment of visceral leishmaniasis [J].
Bern, Caryn ;
Adler-Moore, Jill ;
Berenguer, Juan ;
Boelaert, Marleen ;
den Boer, Margriet ;
Davidson, Robert N. ;
Figueras, Concepcion ;
Gradoni, Luigi ;
Kafetzis, Dimitris A. ;
Ritmeijer, Koert ;
Rosenthal, Eric ;
Royce, Catherine ;
Russo, Rosario ;
Sundar, Shyam ;
Alvar, Jorge .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) :917-924
[10]
*BIODELIVERY SCI I, 2010, BIOR AMPH B